drugset / Trial / NCT03104699
A Study of AGEN2034 in Advanced Tumors and Cervical Cancer
NaSingle-groupOpen-labelTreatment
Summary
This is a 2-part trial: a Phase 1, open-label, dose-escalation study in participants with metastatic or locally advanced solid tumors, with a consecutive Phase 2 expansion to evaluate efficacy in participants with recurrent, unresectable, or metastatic (advanced) cervical cancer that has progressed after a platinum-based treatment regimen.
Timeline
- Start
- 2017-04-11
- Primary completion
- 2022-06-15
- Completion
- 2022-06-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Balstilimab | Monoclonal antibody | 1 mg/kg | Intravenous |
| Subject | Balstilimab | Monoclonal antibody | 3 mg/kg | Intravenous |
| Subject | Balstilimab | Monoclonal antibody | 6 mg/kg | Intravenous |
| Subject | Balstilimab | Monoclonal antibody | 10 mg/kg | Intravenous |